EPISODE · Jun 7, 2026 · 4 MIN
NICE Diabetes Revolution, EU Device JCAs, Clinical Trial Acceleration
Episode 24 — 07 June 2026 NICE's revolutionary diabetes guideline makes SGLT-2 inhibitors first-line therapy while EU HTA regulation expands to high-risk medical devices. FDA accelerated approvals surge and EU clinical trial acceleration shows early progress toward 2030 targets. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Embed this episode
Ready to play
NICE Diabetes Revolution, EU Device JCAs, Clinical Trial Acceleration
No transcript for this episode yet
Similar Episodes
No similar episodes found.